Eladur Patch for Low Back Pain Doesn't Meet Study Goals
Eladur, an investigational transdermal drug patch for low back pain, did not meet goals in a double-blind study, according to a report by its maker, Durect.
Eladur delivers for up to three days bupivacaine, an FDA-approved long-acting local anesthetic used in regional anesthesia for local tissue infiltration, nerve block, and epidural and intrathecal anesthesia.
"Demonstrating efficacy against placebo in a chronic low back pain trial is challenging for any topical locally acting product," said James E. Brown, president and CEO of Durect. "We and Pfizer are continuing to analyze this most recent study and will work together to determine next steps."
Read the Durect report on Eladur.
Read more coverage of low back pain.
- Imaging Doesn't Benefit Most Low Back Pain
- Study Shows Risk Factors for Lower Back Pain in Adolescents
- Study: More Patients Receiving Diagnostic Imaging for Lower Back Pain in ED
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
Latest Articles
- 10 Factors That Affect Surgery Center Value
- Physicians Endoscopy Partners With NY Physicians, Hospital on New Endoscopy Center
- Physicians Endoscopy Partners With NY Physicians, Hospital on New Endoscopy Center
- Covalon Receives FDA Approval for Antimicrobial Silicone Adhesive Film
- New Treatment Uses IV Injections for Severe Migraines
Dow Jones
Company ID [INDEXDJX:.DJI] Last trade:12,598.55 Trade time:4:03PM EDT Value change:▼33.45 (-0.26%)NASDAQ
Company ID [INDEXNASDAQ:.IXIC] Last trade:2,874.04 Trade time:5:16PM EDT Value change:▼19.72 (-0.68%)S&P 500
Company ID [INDEXSP:.INX] Last trade:1,324.80 Trade time:4:32PM EDT Value change:▼5.86 (-0.44%)Channels
